Humanized bcma antibody and bcma-car-t cells

A method of activating immune response against BCMA-expressing tumor cells, the method comprising contacting the tumor cells with engineered immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising:

• a. a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
• 3, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
• 5;
• b. a transmembrane domain selected from the group consisting of a T cell receptor α chain, a T cell receptor β chain, a CD3 zeta chain, a CD28, a CD3ε, a CD45, a CD4, a CD5, a CD8, a CD9, a CD16, a CD22, a CD33, a CD37, a CD64, a CD80, a CD86, a CD134, a CD137, an ICOS, a CD154, and a GITR;
• c. a co-stimulatory domain selected from the group consisting of a CD28, a 4-1BB, a GITR, an ICOS-1, a CD27, an OX-40, and a DAP10;
• and
• d. a CD3zeta activating domain.